following an abbreviated submission:
fosaprepitant (Ivemend 150mg®) is accepted for use within NHSScotland.
Indication under review: prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in paediatric patients aged 6 months to 17 years.
Fosaprepitant is given as part of a combination therapy.
SMC has previously accepted fosaprepitant as part of combination therapy for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy in adults (678/11).
SMC has previously accepted aprepitant for use as part of combination therapy for the prevention of nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to 17 years (1252/17 and 1241/17 respectively). Intravenous fosaprepitant is a pro-drug of oral aprepitant and it offers an alternative with limited budget impact.
Download detailed advice438KB (PDF)
- Medicine name:
- fosaprepitant (Ivemend)
- SMC ID:
- Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.
- Pharmaceutical company
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 12 November 2018